Lipocine Statistics
Total Valuation
Lipocine has a market cap or net worth of $16.58 million. The enterprise value is -$3.09 million.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, before market open.
| Earnings Date | May 8, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Lipocine has 5.35 million shares outstanding. The number of shares has increased by 1.56% in one year.
| Current Share Class | 5.35M |
| Shares Outstanding | 5.35M |
| Shares Change (YoY) | +1.56% |
| Shares Change (QoQ) | +0.08% |
| Owned by Insiders (%) | 2.91% |
| Owned by Institutions (%) | 9.15% |
| Float | 5.19M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.09 |
| Forward PS | 3.45 |
| PB Ratio | 0.87 |
| P/TBV Ratio | 0.87 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.97, with a Debt / Equity ratio of 0.01.
| Current Ratio | 12.97 |
| Quick Ratio | 12.59 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -19.50% and return on invested capital (ROIC) is -15.79%.
| Return on Equity (ROE) | -19.50% |
| Return on Assets (ROA) | -14.56% |
| Return on Invested Capital (ROIC) | -15.79% |
| Return on Capital Employed (ROCE) | -27.69% |
| Revenue Per Employee | $466,054 |
| Profits Per Employee | -$238,593 |
| Employee Count | 17 |
| Asset Turnover | 0.35 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Lipocine has paid $1,236 in taxes.
| Income Tax | 1,236 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -14.13% in the last 52 weeks. The beta is 1.42, so Lipocine's price volatility has been higher than the market average.
| Beta (5Y) | 1.42 |
| 52-Week Price Change | -14.13% |
| 50-Day Moving Average | 4.07 |
| 200-Day Moving Average | 5.15 |
| Relative Strength Index (RSI) | 35.86 |
| Average Volume (20 Days) | 14,866 |
Short Selling Information
The latest short interest is 74,790, so 1.40% of the outstanding shares have been sold short.
| Short Interest | 74,790 |
| Short Previous Month | 77,736 |
| Short % of Shares Out | 1.40% |
| Short % of Float | 1.44% |
| Short Ratio (days to cover) | 2.18 |
Income Statement
In the last 12 months, Lipocine had revenue of $7.92 million and -$4.06 million in losses. Loss per share was -$0.77.
| Revenue | 7.92M |
| Gross Profit | 7.92M |
| Operating Income | -5.29M |
| Pretax Income | -8.49M |
| Net Income | -4.06M |
| EBITDA | -5.26M |
| EBIT | -5.29M |
| Loss Per Share | -$0.77 |
Full Income StatementBalance Sheet
The company has $19.82 million in cash and $153,365 in debt, giving a net cash position of $19.67 million or $3.68 per share.
| Cash & Cash Equivalents | 19.82M |
| Total Debt | 153,365 |
| Net Cash | 19.67M |
| Net Cash Per Share | $3.68 |
| Equity (Book Value) | 19.12M |
| Book Value Per Share | 3.57 |
| Working Capital | 18.92M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$4.95 million and capital expenditures -$89,234, giving a free cash flow of -$5.03 million.
| Operating Cash Flow | -4.95M |
| Capital Expenditures | -89,234 |
| Free Cash Flow | -5.03M |
| FCF Per Share | -$0.94 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -66.82% and -51.19%.
| Gross Margin | 100.00% |
| Operating Margin | -66.82% |
| Pretax Margin | -51.18% |
| Profit Margin | -51.19% |
| EBITDA Margin | -66.39% |
| EBIT Margin | -66.82% |
| FCF Margin | n/a |
Dividends & Yields
Lipocine does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.56% |
| Shareholder Yield | -1.56% |
| Earnings Yield | -24.47% |
| FCF Yield | -30.37% |
Analyst Forecast
The average price target for Lipocine is $10.00, which is 222.58% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.00 |
| Price Target Difference | 222.58% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
The last stock split was on May 12, 2023. It was a reverse split with a ratio of 0.0588235:1.
| Last Split Date | May 12, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.0588235:1 |
Scores
Lipocine has an Altman Z-Score of -3.97 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.97 |
| Piotroski F-Score | 1 |